Why the study?
It was unknown whether the benefits of dapagliflozin in patients with HFrEF and type 2 diabetes varied by background glucose-lowering therapy.
Does dapagliflozin reduce worsening heart failure or cardiovascular death in patients with HFrEF and type 2 diabetes irrespective of background glucose-lowering therapy?
Does dapagliflozin reduce worsening heart failure or cardiovascular death in patients with HFrEF and type 2 diabetes irrespective of background glucose-lowering therapy?
Dapagliflozin improves cardiovascular outcomes in patients with HFrEF and type 2 diabetes regardless of their background glucose-lowering therapy.
Dapagliflozin benefits in HFrEF with T2D are consistent across GLT use and classes; reinforces broad use independent of background therapy.
OBJECTIVE To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. RESULTS In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58–0.88] vs. 0.86 [0.60–1.23]; interaction P = 0.39) and across GLT classes. CONCLUSIONS In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.
No takes yet. Share an insight, caveat, or question.
Docherty et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: